{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:03Z","timestamp":1781179083544,"version":"3.54.1"},"reference-count":0,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":539,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction: Nasopharyngeal carcinoma is a rare malignancy. We conducted an audit of systemic therapies received in palliative setting in carcinoma nasopharynx and studied their outcomes. Methods: Patients who underwent  first-line palliative systemic chemotherapy between January 2014 and April 2017 for carcinoma nasopharynx at the department of medical oncology at authors' institute were selected for this analysis. Toxicities, responses, progression-free survival (PFS), and overall survival (OS) were analyzed. In addition, a Quality-Adjusted Time without Symptoms or Toxicity analysis with threshold utility analysis was performed. Results: Fifty-one patients were included in this analysis. The indication of palliative chemotherapy was locoregionally recurrent disease in 25 (49.0%) patients and metastatic disease in 26 (51.0%) patients. The overall response rate was 62.0% (n = 33). The median PFS was 225 days (95% confidence interval [CI]: 164\u2013274 days) and median OS was 513 days (95% CI: 286\u2013931 days). The restricted mean TOX state duration was 2.6 days (95% CI: 0.3\u20134.9), restricted mean TWiST duration was 219.2 days (95% CI: 184.0\u2013254.4), and restricted mean REL duration was 74.3 days (95% CI: 38.1\u2013110.4). Conclusion: Systemic cytotoxic therapy in nasopharyngeal cancers is associated with high response rates and clinically meaningful PFS; with low duration of time spent in adverse events.<\/jats:p>","DOI":"10.4103\/sajc.sajc_230_18","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T04:49:53Z","timestamp":1564634993000},"page":"173-177","source":"Crossref","is-referenced-by-count":1,"title":["Palliative chemotherapy in carcinoma nasopharynx"],"prefix":"10.25259","volume":"08","author":[{"given":"Vijay M.","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Talreja","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijai","family":"Simha","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Dhumal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Bandekar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Chandrasekharan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2020,12,21]]},"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/sajc.sajc_230_18.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:04Z","timestamp":1781176324000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/palliative-chemotherapy-in-carcinoma-nasopharynx\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":0,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2020,12,21]]},"published-print":{"date-parts":[[2019,7]]}},"URL":"https:\/\/doi.org\/10.4103\/sajc.sajc_230_18","relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}